AMICUS THERAPEUTICS, INC.
DelistedCIK 1178879fmd_0B508M6WA0JY5RDR16HRGBGTPJManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2003 to Dec 31, 2025, 70 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 5 | 37 | 91 | 182 | 261 | 306 | 329 | 399 | 528 | 634 |
| Cost of revenue | 1 | 6 | 14 | 22 | 31 | 34 | 39 | 37 | 53 | 73 |
| Gross profit | 4 | 31 | 77 | 160 | 230 | 271 | 291 | 362 | 475 | 561 |
| Research and development | 105 | 149 | 271 | 286 | 308 | 272 | 277 | 152 | 109 | 136 |
| Selling, general and administrative | 71 | 89 | 127 | 170 | 156 | 193 | 213 | 275 | 323 | 383 |
| Total operating expenses | 186 | 473 | 406 | 464 | 477 | 477 | 503 | 439 | 450 | 528 |
| Operating income | (182) | (442) | (329) | (304) | (247) | (206) | (212) | (77) | 25 | 33 |
| Interest expense | 5 | 17 | 22 | 19 | 22 | 32 | 37 | 50 | 50 | 46 |
| Interest and investment income | 2 | 4 | 10 | 10 | 3 | 1 | 3 | 7 | 5 | 3 |
| Other non-operating income (expense) | (5) | 6 | (6) | (3) | (1) | (3) | 4 | (16) | (9) | 10 |
| Income before taxes | (204) | (449) | (349) | (356) | (274) | (242) | (242) | (150) | (29) | 0 |
| Income tax expense | (4) | (165) | (0) | 0 | 3 | 9 | (5) | 1 | 27 | 27 |
| Net income from continuing operations | (200) | (284) | (349) | (356) | (277) | (250) | (237) | (152) | (56) | (27) |
| Net income | (200) | (284) | (349) | (356) | (277) | (250) | (237) | (152) | (56) | (27) |
| Net income to common shareholders | (200) | – | – | – | – | – | – | – | – | – |